Adrenoceptor (Adrenergic receptor) (AR)

Adrenoceptors, also known as adrenergic receptors, are a class of G protein-coupled receptors (GPCRs) that mediate the physiological responses to the endogenous catecholamines, epinephrine and norepinephrine [StatPearls: NBK534230]. They are broadly categorized into alpha (α1, α2) and beta (β1, β2, β3) types, each associated with distinct G protein signaling subunits and tissue distributions [IUPHAR: Adrenoceptors]. Alpha-1 receptors primarily mediate smooth muscle contraction in the vasculature and genitourinary tract via the Gq pathway, while alpha-2 receptors often act as presynaptic inhibitory receptors via the Gi pathway to regulate neurotransmitter release [PubMed: 29021037]. Beta-1 receptors are predominantly found in the heart, where they increase rate and contractility; beta-2 receptors facilitate bronchodilation and vasodilation; and beta-3 receptors are involved in lipolysis and thermogenesis, all primarily signaling through the Gs-cAMP pathway [UniProt: P08588, P07550]. These receptors are among the most important therapeutic targets in modern medicine, with applications ranging from treating hypertension and heart failure with beta-blockers to managing asthma with beta-2 agonists [NIH: Adrenergic Agents]. Due to their widespread distribution, selectivity is a key pharmacological consideration to avoid adverse effects like bronchoconstriction or metabolic interference [StatPearls: NBK534230]. Overall, the adrenoceptor system is a fundamental component of the autonomic nervous system, regulating critical homeostatic functions across the cardiovascular, respiratory, and metabolic systems.

Other names

Adrenergic receptorAdrenoreceptorAlpha-adrenoceptorBeta-adrenoceptorAlpha-adrenergic receptorBeta-adrenergic receptorAlpha and beta adrenoceptors

Drugs targeting adrenoceptors act as either agonists or antagonists to modulate the sympathetic nervous system. Agonists mimic the action of endogenous catecholamines to activate G protein-mediated signaling pathways: alpha-1 agonists trigger the Gq-PLC-IP3 pathway leading to calcium release and muscle contraction, while beta agonists activate the Gs-adenylyl cyclase-cAMP pathway to stimulate cardiac activity or relax smooth muscle [StatPearls: NBK534230]. Antagonists, such as beta-blockers or alpha-blockers, competitively bind to these receptors to inhibit the effects of sympathetic stimulation, thereby reducing blood pressure, heart rate, or smooth muscle tone [IUPHAR: Adrenoceptors].